Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00906 ...
Drug Name Tiagabine
Molecular Weight 375.548
Molecular Formula C20H25NO2S2
CAS Number 115103-54-3
SMILES CC1=C(SC=C1)C(=CCCN1CCC[C@H](C1)C(O)=O)C1=C(C)C=CS1
External Links
DRUGBANK DB00906
T3DB T3D2926
PubChem Compound 60648
PDR 2331
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 2.6 - 2.6 - DRUGBANK

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Absorption 95.0 % >95 % DRUGBANK
Bioavailability 90.0 % ~90 % PO, oral; The Pharmacological Basis of Therapeutics
C Max 122.0 ng/ml 122±36 ng/ml Oral single dose; adults; normal,healthy; The Pharmacological Basis of Therapeutics
C Max 69.0 ng/ml 69±22 ng/ml Oral multiple dose; adults; normal,healthy; The Pharmacological Basis of Therapeutics
T Max 0.90 h 0.9±0.5 h Oral single dose; adults; normal,healthy; The Pharmacological Basis of Therapeutics
T Max 1.5 h 1.5±1.0 h Oral multiple dose; adults; normal,healthy; The Pharmacological Basis of Therapeutics
Clearance 6.5 L/h 109.0 ml/min normal,healthy; DRUGBANK
Clearance 0.12 L/h/kg 2.0±0.4 ml/min/kg apparent clearance; PO, oral; normal,healthy; Male, men; patients; Children ↑ ;hepatopathy，LD ↓ ;RD, renal impairment, Renal disease，including uremia → ;epilepsy ↑ ; The Pharmacological Basis of Therapeutics
Clearance 0.0960 L/h/kg 1.6 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 1.3 L/kg 1.3±0.4 L/kg Apparent volume of distribution; PO, oral; normal,healthy; Male, men; patients; The Pharmacological Basis of Therapeutics
Volume of Distribution 1.1 L/kg 1.1 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 8.0 h 7-9 h DRUGBANK
Half-life 8.0 h 7-9 h PO, oral; chronic liver disease ↑ ; The Pharmacological Basis of Therapeutics
Half-life 10.0 h 10 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Eliminate Route 24.5 % 24.5 % Urinary excretion; PO, oral; DRUGBANK
Eliminate Route 61.7 % 61.7 % Faeces excretion; PO, oral; DRUGBANK
Eliminate Route 2.0 % ~2 % PO, oral; Unchanged drug; DRUGBANK
Eliminate Route 1.5 % 1-2 % Urinary excretion; adults; normal,healthy; epilepsy; human, homo sapiens; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 96.0 % 96 % DRUGBANK
Protein Binding 96.0 % 96 % adults; normal,healthy; epilepsy; human, homo sapiens; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for children 0.8 mg/kg/day 0.8 mg/kg/day PO, oral Gabitril tiagabine hydrochloride PDR
Max dose for adolescents 32.0 mg/day 32 mg/day PO, oral Gabitril tiagabine hydrochloride PDR
Max dose for adults 56.0 mg/day 56 mg/day PO, oral Gabitril tiagabine hydrochloride PDR
Max dose for elderly 56.0 mg/day 56 mg/day PO, oral Gabitril tiagabine hydrochloride PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1